Skip to content

Study · Not a test of the peptide alone · 2008

4 results

Oral absorption enhancement of dipeptide L-Glu-L-Trp-OH by lipid and glycosyl conjugation.

Bergeon JA, Chan YN, Charles BG, Toth I

Biopolymers1 Jan 2008Cited by 11 (Europe PMC)

PMID18428206 (opens in a new tab)DOI10.1002/bip.21003 (opens in a new tab)PepBankPUB-18428206
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymogen (oglufanide).

  1. 01LabNot a test of Thymogen (oglufanide) aloneEx vivo tissueSafety outcome

    In red blood cells, synthesized Glu-Trp derivatives showed no toxicity at 200 microM in a haemolysis assay.

    In plain wordsIn lab tests, synthesized Glu-Trp derivatives showed no red blood cell toxicity at the tested concentration.

    Peptide
    Thymogen (oglufanide)
    Outcome
    No significant changeHemolytic toxicity
    Study

    n: not reported in source

    red blood cells
    Outcome group
    Adverse events · Pharmacology

    Measurements

    Test concentration
    200 microM
    haemolysis assay of synthesized peptides

    Source sentences

    Summary
    The synthesized peptides showed no sign of toxicity to red blood cells at 200 microM (haemolysis assay)

    In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymogen (oglufanide).

  2. 02LabNot a test of Thymogen (oglufanide) aloneIn vitro (cells)Activity measurement

    In Caco-2 tests, several Glu-Trp derivatives showed greatly enhanced apparent permeability.

    In plain wordsIn cells, several Glu-Trp derivatives showed greater apparent permeability.

    Peptide
    Thymogen (oglufanide)
    Outcome
    IncreaseApparent permeability
    Study

    humann: not reported in source

    Caco-2 monolayers
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    Several derivatives also saw their apparent permeability values greatly enhanced

    In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymogen (oglufanide).

  3. 03LabNot a test of Thymogen (oglufanide) aloneIn vitro (cells)Activity measurement

    In Caco-2 monolayers, one Glu-Trp conjugate released the initial dipeptide after penetration.

    In plain wordsIn cells, one Glu-Trp conjugate released the original dipeptide after passing through the cell layer.

    Peptide
    Thymogen (oglufanide)
    Outcome
    Not applicableRelease of initial dipeptide after penetration
    Study

    humann: not reported in source

    Caco-2 monolayers
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    one of the conjugates tested proved to be able to release the initial dipeptide after penetrating Caco-2 monolayers.

    In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymogen (oglufanide).

  4. 04LabNot a test of Thymogen (oglufanide) aloneIn vitro (cell-free)Activity measurement

    In Caco-2 homogenates, Glu-Trp conjugates usually showed significantly increased resistance to enzymatic hydrolysis, particularly C-terminal conjugates.

    In plain wordsIn lab tests, Glu-Trp conjugates usually resisted enzyme breakdown better, particularly conjugates modified at the C-terminal end.

    Peptide
    Thymogen (oglufanide)
    Outcome
    IncreaseResistance to enzymatic hydrolysis
    Study

    humann: not reported in source

    Caco-2 homogenates
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    their resistance against enzymatic hydrolysis, assessed in Caco-2 homogenates, was usually significantly increased, particularly for the C-terminal conjugates.

    In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymogen (oglufanide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.